The most recent suit, filed last week, alleges that the researcher misrepresented and falsified data related to prostate cancer biomarkers after Onconome sponsored "millions of dollars" of research at his University of Pittsburgh and Johns Hopkins University labs to see if the technology could lead to a clinical diagnostic test for prostate cancer.
Scientific co-founders of Sentient, which is developing embolization therapy technology and site-specific drug delivery methods to treat cancer and other medical conditions, include researchers from Brown University and Johns Hopkins University.
By sequencing the entire PTK gene family in dozens of individuals with melanoma, NIH and Johns Hopkins researchers found ERBB4, or HER4, mutations in nearly a fifth of those tested, suggesting a subset of patients may respond to drugs targeting the gene.
The so-called Activate for NIH program, which will match postdocs with entrepreneurs to create companies, builds upon the success of a previous NSF-funded initiative led by UMBC that trained mid-career women entrepreneurs to create tech-based startups in the state.
Using a data from a GWAS of almost 1,700 hepatitis C patients, researchers from Duke and Johns Hopkins University and Schering-Plough Research Institute have identified a biomarker for HCV treatment response.
Jenny Van Eyk and others at JHU have discovered that during myocardial ischemia, the albumin molecule can change, which may prove clinically relevant. Protea plans to apply the findings to develop products to analyze albumin from the bloodstream.